nVerses Capital’s DexCom DXCM Stock Holding History

nVerses Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,800	Closed	-$431K	–	1103
2024 Q2	$431K	Buy	3,800 +2,400	+171%	+$303K	0.26%	121
2024 Q1	$194K	Buy	+1,400	New	+$176K	0.47%	38

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

nVerses Capital's DXCM Position: Q3 2024 in Review

nVerses Capital sold out of DexCom (DXCM) in Q3 2024, closing a stake of 3,800 shares — an estimated $431K sold.

nVerses Capital first reported a position in DXCM in Q1 2024 and held it in 2 quarters. The position peaked at $431K in Q2 2024. 889 funds tracked by Wall St. Rank hold DXCM as of Q3 2024.

nVerses Capital reported no remaining DexCom position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 3,800 DexCom shares in Q3 2024, an estimated $431K.
nVerses Capital first reported a position in DexCom in Q1 2024 and held it in 2 quarters.
nVerses Capital's DexCom position peaked at $431K in Q2 2024.
889 funds tracked by Wall St. Rank held DexCom as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.